Recently, another drug used to treat a rare disease has announced its withdrawal from the Chinese market, drawing widespread concern from patient communities and the medical field. The medication targets an extremely rare inherited metabolic disorder, with fewer than 100 diagnosed patients nationwide. The pharmaceutical company stated that due to the tiny patient population, limited market demand, and high R&D and production costs, long-term commercial sustainability is unfeasible, leading to the decision to discontinue supply in China.Drugs for rare diseases—often called ‘orphan drugs’—typically face low commercial incentives because of their small target populations and narrow profit margins. Although China has introduced supportive policies in recent years, such as expedited regulatory review and inclusion in national health insurance negotiations, practical implementation remains challenging. For patients who rely on this medication to survive, discontinuation could mean interrupted treatment or even life-threatening consequences.Experts urge the establishment of a more robust rare disease support system, including multi-stakeholder payment models combining government subsidies, charitable aid, and commercial insurance to ease the burden on pharmaceutical companies while ensuring patient access. Additionally, promoting domestic orphan drug development and creating a national rare disease registry are crucial steps toward improving overall preparedness. This latest drug withdrawal underscores the vulnerability of rare disease patients in healthcare resource allocation and highlights the urgent need for systemic solutions.
近日，又一款用于治疗罕见病的药物宣布将退出中国市场，引发患者群体和医疗界的广泛关注。该药物主要用于治疗一种发病率极低的遗传性代谢疾病，全国患者不足百人。药企方面表示，由于患者人数稀少、市场需求有限，加上高昂的研发与生产成本，长期难以实现商业可持续性，因此决定停止在中国的供应。罕见病药物通常被称为“孤儿药”，因其目标人群小、利润空间有限，药企缺乏研发和销售动力。尽管中国近年来出台了多项鼓励政策，包括加快审评审批、纳入医保谈判等，但实际落地仍面临挑战。对于依赖该药维持生命的患者而言，断供可能意味着治疗中断甚至生命危险。专家呼吁，应进一步完善罕见病保障体系，探索多方共付机制，如政府补贴、慈善援助与商业保险结合，以减轻药企负担并保障患者用药可及性。同时，推动本土罕见病药物研发和建立国家级罕见病登记系统，也是提升整体应对能力的关键举措。此次药品退出事件再次凸显了罕见病群体在医疗资源分配中的脆弱地位，亟需制度性解决方案。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/16702.html